Vertex Pharmaceuticals Inc. stock rises Wednesday, still underperforms market
Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.11% to $491.64 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.12% to 5,842.63 and the Dow Jones Industrial Average DJIA rising 1.14% to 43,006.59.
Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?
With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston, Massachusetts-based company engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)
Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price
Vertex Pharmaceuticals Leads 3 Value Stocks Offering Estimated Intrinsic Value
As U.S. markets grapple with the implications of newly imposed tariffs and economic uncertainties, investors are increasingly seeking opportunities in undervalued stocks that may offer intrinsic value amid broader market declines.
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $408.00
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 in a research note issued to investors on Thursday,Benzinga reports. Royal Bank of Canada currently has a sector perform rating on the pharmaceutical company’s stock.
Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market
The stock's rise snapped a four-day losing streak.
Vertex Pharmaceuticals Incorporated (VRTX): Among Renaissance Technologies Portfolio’s Top Stock Picks
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other Renaissance Technologies portfolio’s top stock picks.
Vertex non-opioid pain drug picked up by UnitedHealth
Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...
Vertex Pharma drops as UnitedHealth offers Tier 3 coverage for new pain medicine
Vertex Pharmaceuticals (NASDAQ:VRTX) ended a four-day winning streak on Thursday after UnitedHealth (NYSE:UNH) placed its new ...
Investing.com India1h
UnitedHealth includes Vertex’s non-opioid painkiller in coverage, but at a higher cost - Bloomberg
Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ: VRTX ).’s newly approved non-opioid pain medication, Journavx, has been included in UnitedHealth Group Inc (NYSE: UNH ).’s coverage, according to ...
BioSpace6d
Vertex Severs Liver Gene Therapies Partnership With Verve
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Analysts Conflicted on These Healthcare Names: Clearside Biomedical (CLSD) and Virpax Pharmaceuticals (VRPX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Clearside Biomedical (CLSD – Research ...
Top Biotech Stocks To Research – March 4th
AbbVie, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, and Illumina are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks represent ...